What Just Happened To Alnylam Stock?
Yahoo · 30 de oct de 2026
For questions about this article or underlying research, email help@trefis.com.
Gilead Sciences, Inc.
GILD
Sí, existe CEDEAR de GILD en Argentina. Operás bajo el ticker GILD en BYMA, con ratio 4:1 respecto a la acción en NASDAQ. Ratios y calculadora Ver próximos dividendos.
Empresa subyacente
HealthcareDrug Manufacturers - General
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company has a partnership with Pan American Health Organization (PAHO) to accelerate access to lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO member states in Latin America and the Caribbean. The company was incorporated in 1987 and is headquartered in Foster City, California.
- País
- United States
- Empleados
- 17.000
- Sitio web
- gilead.com
Precio histórico
Últimos 235 días · 12/11/25 — 29/10/26
+49.60%
Cotización y datos
NASDAQRatio 4:1 · Subyacente GILD
CEDEAR (ARS)
Precio
$ 71.125
Var. %
+4,67%
Volumen operado
5.087
Subyacente (USD)
Precio GILD
US$ 170,61
Teórico (precio / ratio)
GILD ÷ 4
US$ 42,65
Dólar MEP (GILDD)
Dividendos
Yield y fechas del subyacente vía Yahoo Finance. Ver calendario de dividendos.
Yield (USD)
2,0 %
Frecuencia (estimada)
Trim.
Próxima ex-date
sin fecha
Próximo pago
sin fecha
Cobro estimado (anual)
Dividendo anual USD ÷ ratio 4
USD 0,82
Preguntas frecuentes
¿Existe CEDEAR de GILD en Argentina?
Sí, existe el CEDEAR de GILD (Gilead Sciences, Inc.) en la Bolsa de Comercio de Buenos Aires (BYMA). Su ticker local es GILD.
¿Cuál es el ticker del CEDEAR de Gilead Sciences, Inc.?
El ticker del CEDEAR de Gilead Sciences, Inc. en Argentina es GILD. La acción subyacente cotiza en NASDAQ con el símbolo GILD.
¿Cuál es el ratio del CEDEAR GILD?
El CEDEAR GILD tiene un ratio de 4:1. Eso significa que 4 CEDEARs equivalen a 1 acción de GILD.
¿Cuánto vale el CEDEAR GILD hoy?
El CEDEAR GILD cotiza hoy a $ 71.125 en pesos argentinos, con una variación diaria de +4,67%.
¿Cuánto vale la acción GILD en dólares?
CEDEARs similares
Otros CEDEARs de Salud.
Noticias
Gilead's HIV Franchise Supports Growth Outlook, RBC Says
Yahoo · 30 de oct de 2026
Gilead Sciences (GILD) continues to benefit from strong demand for its HIV medicines, helping suppor
Gilead (GILD) Q3 2026 Earnings Call Transcript
Yahoo · 30 de oct de 2026
Base business sales surged 16%, marking strongest growth in over a decade.
